Partner Therapeutics Announces Start of Phase 3 Portion of Clinical Study of Leukine® in Combination with Ipilumimab and Nivolumab in Front Line Treatment of Melanoma

 

NCI sponsored, ECOG-ACRIN study advances after successful planned interim analysis

 

Lexington, MA – September 11, 2020 — Partner Therapeutics, Inc. (PTx), a commercial biotech company, announces the resumption of enrollment in the National Cancer Institute (NCI) sponsored Study EA61411 being conducted by ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and led by Study Chair F. Stephen Hodi, MD, Director of the Center for Immuno-Oncology at Dana-Farber Cancer Institute and Study Co-Chair Ahmad Tarhini, MD, PhD., Professor of Oncologic Sciences and Director of Cutaneous ...

Continue Reading →
0

Partner Therapeutics Initiates Patient Enrollment in U.S. Clinical Trial Evaluating Leukine® (rhuGM-CSF, sargramostim) in COVID-19 Patients

 

Study builds on extensive research showing that granulocyte-macrophage colony stimulating factor (GM-CSF) is needed for effective immune function in the lungs

iLeukPulm Phase 2 Clinical TrIal Supported by $35 Million Contract from U.S. Department of Defense

 

LEXINGTON, MA – August 25, 2020 — Partner Therapeutics, Inc. (PTx), a commercial biotechnology company, announced today that the first patient has been enrolled in the iLeukPulm clinical trial, a randomized phase 2 study of inhaled Leukine (sargramostim, rhu-GM-CSF) in hospitalized COVID-19 patients with acute hypoxemia ...

Continue Reading →
0

Partner Therapeutics Announces $35 Million Contract with U.S. Department of Defense for Advanced Development and Emergency Use of Leukine® (rhuGM-CSF) for COVID-19 Acute Hypoxemic Respiratory Failure (AHRF)

 

Funding will support two randomized, multi-center clinical trials in COVID-19 patients, expansion of manufacturing capacity and potential Emergency Use Authorization (EUA) filing

LEXINGTON, MA – August 4, 2020 — Partner Therapeutics, Inc. (PTx), a commercial biotechnology company, today anounced a $35 million milestone-based Other Transaction Agreement (OTA) with the U.S. Department of Defense (DOD) to fund two clinical studies of inhaled Leukine® (sargramostim, rhu-Granulocyte Macrophage-Colony Stimulating Factor “GM-CSF”) in patients with COVID-19 associated acute hypoxemia.  Through the DOD’s Chemical Biological Defense ...

Continue Reading →
0

Partner Therapeutics Announces Initiation of Clinical Trial Evaluating Leukine® in T Cell Replete HLA-mismatched Haploidentical Stem Cell Transplant

 

LEXINGTON, MA. June 11, 2020 – Partner Therapeutics, a commercial biotechnology company, announces the enrollment of the first patient dosed in a Phase II investigator-initiated study evaluating the efficacy and safety of Leukine® (sargramostim, rhu-GM-CSF) in T cell replete HLA-mismatched haploidentical stem cell transplant recipients who are receiving post-transplant cyclophosphamide (NCT04237623).

The study will enroll patients with high risk hematologic malignancies who are the recipients of a haploidentical cell transplant. The trial will evaluate the effectiveness of Leukine compared to a matched ...

Continue Reading →
0

Partner Therapeutics Announces Initiation of Clinical Trial to Evaluate Leukine® in Respiratory Illness in Patients with COVID-19 at Singapore General Hospital

Trial expands global clinical research of Leukine in treatment of COVID-19 including multi-center trial underway in Belgium

Lexington, MA – May 28, 2020 — Partner Therapeutics, Inc. (PTx), a commercial biotech company, announces the initiation of an investigator-initiated randomized, double-blind, placebo-controlled clinical trial of Leukine(sargramostim, rhu-GM-CSF) in patients with acute respiratory failure associated with COVID-19, conducted at Singapore General Hospital (NCT04400929).  The study will evaluate the effect of Leukine on lung function and other important patient outcomes.

“There is large ...

Continue Reading →
0

Partner Therapeutics Announces Initiation of Clinical Trial to Evaluate Leukine® in Patients with COVID-19 Associated Respiratory Illness

SARPAC trial initiated at the University Hospital Ghent in Belgium

Lexington, MA – March 24, 2020 /PRNewswire/ — Partner Therapeutics, Inc. (PTx) announced that Leukine® (sargramostim, rhu-GM-CSF) is being assessed in the SARPAC trial (sargramostim in patients with acute hypoxic respiratory failure due to COVID-19 – EudraCT #2020-001254-22) at University Hospital Ghent to treat patients with respiratory illness associated with COVID-19.  Major medical centers in Germany, Italy and Spain are considering joining the study.  The study will evaluate the effect ...

Continue Reading →
0
Page 2 of 2 12